4DMedical Secures $100M+ to Scale U.S. Respiratory Imaging Rollout

What You Should Know:

–  4DMedical, the leader in software-based respiratory imaging technology, today announced US$100+ million (AU$150 million) in new institutional placement.

– The investment will primarily be leveraged to accelerate U.S. adoption of its class-leading “CT:VQ” product and significantly boost research and development—bolstering 4D’s technology lead in software-based lung imaging. Backed by new institutional funding, 4DMedical is advancing its respiratory imaging technology and expanding the U.S. rollout of its FDA-cleared CT:VQ software.

4DMedical Advances Software-Based Lung Imaging as CT:VQ Gains Rapid Adoption Across Leading U.S. Health Systems

4DMedical Limited (ASX:4DX) is a global medical technology company developing advanced software-based cardiothoracic imaging solutions that combine proprietary algorithms with artificial intelligence. Its platform extracts deep, quantitative insights from routine clinical imaging, enabling clinicians to assess lung function and cardiopulmonary disease with a level of precision not achievable through conventional imaging alone.

4DMedical’s technology equips pulmonologists, radiologists, and multidisciplinary hospital teams with patient-specific, regional lung-function data that support diagnosis, disease monitoring, treatment selection, and surgical planning. Designed for seamless integration into existing clinical workflows, the company’s SaaS-based solutions emphasize actionable intelligence, operational efficiency, and real-world usability across a broad spectrum of respiratory conditions.

A flagship offering, CT:VQ, is an FDA-cleared software-as-a-service platform that derives ventilation and perfusion insights directly from standard CT imaging. Within four months of FDA clearance, CT:VQ was deployed at four elite U.S. academic medical centers: Stanford Health Care, Cleveland Clinic, University of Miami Health System, and UC San Diego Health. This rapid uptake underscores growing clinical demand for quantified, functional lung information that extends beyond traditional structural imaging and is increasingly critical for longitudinal disease assessment and treatment planning.

“This is an extraordinarily important and validating milestone,” said Andreas Fouras, Founder and CEO of 4DMedical. “It reflects global recognition of our technological leadership, the clinical relevance of products such as CT:VQ, and the significant growth opportunity ahead in the U.S. market. With strengthened institutional backing and balance sheet flexibility, we are positioned to scale adoption, accelerate R&D, deepen strategic partnerships, and lead the global market for software-based lung imaging.”

The recent funding strengthens 4DMedical’s ability to support hospitals and health systems as adoption scales across the United States. Capital will be deployed to expand commercial reach across academic medical centers and integrated delivery networks, enhance customer success and training programs to support consistent clinical utilization, and advance research and development across functional lung imaging applications. The company will also invest in operational flexibility to sustain long-term clinical partnerships and pursue additional growth opportunities.

Following the raise, 4DMedical reported a pro forma cash position exceeding US$130 million (AU$200 million), providing a strong foundation for U.S. expansion and support of a growing installed base. The company delivers its products through a SaaS model engineered to integrate with existing hospital IT and imaging infrastructure, and continues to build strategic partnerships, including with Philips, to facilitate broader adoption pathways and enterprise-scale deployment.

Together, these developments position 4DMedical as a defining player in the shift toward functional, software-driven lung imaging—bringing quantified cardiopulmonary insights into routine clinical care at scale.

What You Should Know:

–  4DMedical, the leader in software-based respiratory imaging technology, today announced US$100+ million (AU$150 million) in new institutional placement.

– The investment will primarily be leveraged to accelerate U.S. adoption of its class-leading “CT:VQ” product and significantly boost research and development—bolstering 4D’s technology lead in software-based lung imaging. Backed by new institutional funding, 4DMedical is advancing its respiratory imaging technology and expanding the U.S. rollout of its FDA-cleared CT:VQ software.

4DMedical Advances Software-Based Lung Imaging as CT:VQ Gains Rapid Adoption Across Leading U.S. Health Systems

4DMedical Limited (ASX:4DX) is a global medical technology company developing advanced software-based cardiothoracic imaging solutions that combine proprietary algorithms with artificial intelligence. Its platform extracts deep, quantitative insights from routine clinical imaging, enabling clinicians to assess lung function and cardiopulmonary disease with a level of precision not achievable through conventional imaging alone.

4DMedical’s technology equips pulmonologists, radiologists, and multidisciplinary hospital teams with patient-specific, regional lung-function data that support diagnosis, disease monitoring, treatment selection, and surgical planning. Designed for seamless integration into existing clinical workflows, the company’s SaaS-based solutions emphasize actionable intelligence, operational efficiency, and real-world usability across a broad spectrum of respiratory conditions.

A flagship offering, CT:VQ, is an FDA-cleared software-as-a-service platform that derives ventilation and perfusion insights directly from standard CT imaging. Within four months of FDA clearance, CT:VQ was deployed at four elite U.S. academic medical centers: Stanford Health Care, Cleveland Clinic, University of Miami Health System, and UC San Diego Health. This rapid uptake underscores growing clinical demand for quantified, functional lung information that extends beyond traditional structural imaging and is increasingly critical for longitudinal disease assessment and treatment planning.

“This is an extraordinarily important and validating milestone,” said Andreas Fouras, Founder and CEO of 4DMedical. “It reflects global recognition of our technological leadership, the clinical relevance of products such as CT:VQ, and the significant growth opportunity ahead in the U.S. market. With strengthened institutional backing and balance sheet flexibility, we are positioned to scale adoption, accelerate R&D, deepen strategic partnerships, and lead the global market for software-based lung imaging.”

The recent funding strengthens 4DMedical’s ability to support hospitals and health systems as adoption scales across the United States. Capital will be deployed to expand commercial reach across academic medical centers and integrated delivery networks, enhance customer success and training programs to support consistent clinical utilization, and advance research and development across functional lung imaging applications. The company will also invest in operational flexibility to sustain long-term clinical partnerships and pursue additional growth opportunities.

Following the raise, 4DMedical reported a pro forma cash position exceeding US$130 million (AU$200 million), providing a strong foundation for U.S. expansion and support of a growing installed base. The company delivers its products through a SaaS model engineered to integrate with existing hospital IT and imaging infrastructure, and continues to build strategic partnerships, including with Philips, to facilitate broader adoption pathways and enterprise-scale deployment.

Together, these developments position 4DMedical as a defining player in the shift toward functional, software-driven lung imaging—bringing quantified cardiopulmonary insights into routine clinical care at scale.